Barnette et al., Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. NEJM Evid 2022;1(9). July 2022|Sabizabulin|
Markowski M et al. A Phase Ib/II study of sabizabulin, a novel oral cytoskeleton disruptor, in men with metastatic castration-resistant prostate cancer with progression on an androgen receptor targeting agent. Clin Can Res 2022, doi:10.1158/1078-0432.CCR-22-0162. July 2022|Sabizabulin|
Gordon M et al. Phase II study of oral sabizabulin for the treatment of SARS-CoV-2 in hospitalized patients at high risk for ARDS. ECCMID, April 23, 2022. April 2022|Sabizabulin|
Foyez M et al. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer Cancer Letters 495:76, 2020. December 2020|Sabizabulin|
Deng S et al. An orally available tubulin inhibitor, VERU-111, suppresses triple negative breast cancer tumor growth and metastasis and bypasses taxane resistance. Mol Cancer Ther 19:348-363, 2020. February 2020|Sabizabulin|
